Evidence map›Paper›PMID 31520523›Full record

ArticleESC heart failure2019

Impact of statins on cellular respiration and de-differentiation of myofibroblasts in human failing hearts.

Larisa Emelyanova, Amar Sra, Eric G Schmuck, Amish N Raval, Francis X Downey, Arshad Jahangir, Farhan Rizvi, Gracious R Ross

Open access · goldAbstract readComparative Study
In one paragraph

Article in ESC heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Statins and Cardiomyocyte Metabolism, Friend or Foe?Journal of cardiovascular development and disease · 2023
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Functional Regulation of KFrontiers in pharmacology · 2022
    Review
  18. Article
  19. Review
  20. Pleiotropic effects of statins: A focus on cancer.Biochimica et biophysica acta. Molecular basis of disease · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Larisa EmelyanovaCenter for Integrative Research on Cardiovascular Aging, Aurora Health Care, St. Luke's Medical Center, 2900 W. Oklahoma Ave, Milwaukee, WI, 53215, USA.
Amar SraCenter for Integrative Research on Cardiovascular Aging, Aurora Health Care, St. Luke's Medical Center, 2900 W. Oklahoma Ave, Milwaukee, WI, 53215, USA.
Eric G SchmuckDepartment of Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Amish N RavalDepartment of Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Francis X DowneyAurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Milwaukee, WI, USA.
Arshad JahangirAurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Milwaukee, WI, USA.
Farhan RizviCenter for Integrative Research on Cardiovascular Aging, Aurora Health Care, St. Luke's Medical Center, 2900 W. Oklahoma Ave, Milwaukee, WI, 53215, USA.
Gracious R RossCenter for Integrative Research on Cardiovascular Aging, Aurora Health Care, St. Luke's Medical Center, 2900 W. Oklahoma Ave, Milwaukee, WI, 53215, USA.
Aurora St. Luke's Medical Center · USUniversity of Wisconsin–Madison · USAurora Health Care · US

Funding

Aurora Health Care, Cardiovascular Surgical Research Award 570-5028
6 · The paper itself

Abstract

aimsFibroblast to myofibroblast trans-differentiation with altered bioenergetics precedes cardiac fibrosis (CF). Either prevention of differentiation or promotion of de-differentiation could mitigate CF-related pathologies. We determined whether 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors-statins, commonly prescribed to patients at risk of heart failure (HF)-can de-differentiate myofibroblasts, alter cellular bioenergetics, and impact the human ventricular fibroblasts (hVFs) in HF patients. METHODS AND

resultsEither in vitro statin treatment of differentiated myofibroblasts (n = 3-6) or hVFs, isolated from human HF patients under statin therapy (HF + statin) vs. without statins (HF) were randomly used (n = 4-12). In vitro, hVFs were differentiated by transforming growth factor-β1 (TGF-β1) for 72 h (TGF-72 h). Differentiation status and cellular oxygen consumption rate (OCR) were determined by α-smooth muscle actin (α-SMA) expression and Seahorse assay, respectively. Data are mean ± SEM except Seahorse (mean ± SD); P < 0.05, considered significant. In vitro, statins concentration-dependently de-differentiated the myofibroblasts. The respective half-maximal effective concentrations were 729 ± 13 nmol/L (atorvastatin), 3.6 ± 1 μmol/L (rosuvastatin), and 185 ± 13 nmol/L (simvastatin). Mevalonic acid (300 μmol/L), the reduced product of HMG-CoA, prevented the statin-induced de-differentiation (α-SMA expression: 31.4 ± 10% vs. 58.6 ± 12%). Geranylgeranyl pyrophosphate (GGPP, 20 μmol/L), a cholesterol synthesis-independent HMG-CoA reductase pathway intermediate, completely prevented the statin-induced de-differentiation (α-SMA/GAPDH ratios: 0.89 ± 0.05 [TGF-72 h + 72 h], 0.63 ± 0.02 [TGF-72 h + simvastatin], and 1.2 ± 0.08 [TGF-72 h + simvastatin + GGPP]). Cellular metabolism involvement was observed when co-incubation of simvastatin (200 nmol/L) with glibenclamide (10 μmol/L), a K

conclusionsThis study demonstrates the de-differentiating effect of statins, the underlying GGPP sensitivity, reduced OCR with potential activation of K

Indexed as

ActinsCell DifferentiationEnergy MetabolismEnzyme InhibitorsFibroblastsFibrosisHeart FailureHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMevalonic AcidMitochondria, HeartMyofibroblastsOligomycinsOxygen ConsumptionPolyisoprenyl PhosphatesRespirationACTA2 protein, humanActinsEnzyme Inhibitorsgeranylgeranyl pyrophosphateHydroxymethylglutaryl-CoA Reductase InhibitorsMevalonic AcidOligomycinsPolyisoprenyl PhosphatesSimvastatinTGFB1 protein, humanTransforming Growth Factor beta1Cardiac fibrosisDe-differentiationGeranylgeranyl pyrophosphateMitochondriaStatins

Identifiers

PMID31520523
PMCPMC6816080
OpenAlexW2972569830

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.